These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 19218892

  • 21. Microbicides and other topical strategies to prevent vaginal transmission of HIV.
    Lederman MM, Offord RE, Hartley O.
    Nat Rev Immunol; 2006 May; 6(5):371-82. PubMed ID: 16639430
    [Abstract] [Full Text] [Related]

  • 22. Push is on for increased microbicide R&D funds.
    Contracept Technol Update; 2000 Jun; 21(6):69-70. PubMed ID: 12295924
    [Abstract] [Full Text] [Related]

  • 23. Advances in microbicide vaginal rings.
    Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
    [Abstract] [Full Text] [Related]

  • 24. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
    Aranha CC, Gupta SM, Reddy KV.
    Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
    [Abstract] [Full Text] [Related]

  • 25. Microbicidal spermicide or spermicidal microbicide?
    Gupta G.
    Eur J Contracept Reprod Health Care; 2005 Dec; 10(4):212-8. PubMed ID: 16448947
    [Abstract] [Full Text] [Related]

  • 26. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials.
    Fichorova RN, Lai JJ, Schwartz JL, Weiner DH, Mauck CK, Callahan MM.
    Cytokine; 2011 Jul; 55(1):134-40. PubMed ID: 21530305
    [Abstract] [Full Text] [Related]

  • 27. [The acceptability on vaginal microbicides to prevent human immunodeficiency virus/sexually transmitted diseases].
    Han L, Wu ZL.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):196-8. PubMed ID: 19565887
    [No Abstract] [Full Text] [Related]

  • 28. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides.
    Mauck CK, Straten Av.
    J Acquir Immune Defic Syndr; 2008 Sep 01; 49(1):64-9. PubMed ID: 18667920
    [Abstract] [Full Text] [Related]

  • 29. Topical microbicides: the time has come.
    Dhawan D, Keller M, Klotman ME.
    AIDS Read; 2006 Mar 01; 16(3):144-8, 155-8, 161; discussion 148, 156-7. PubMed ID: 16538955
    [Abstract] [Full Text] [Related]

  • 30. A cause for optimism: microbicides pipeline shows promise.
    McCord A.
    Proj Inf Perspect; 2008 Sep 01; (46):24-5. PubMed ID: 19048680
    [No Abstract] [Full Text] [Related]

  • 31. Vaginal microbicides: a priority need for women's health.
    Fathalla MF.
    Curr Womens Health Rep; 2003 Aug 01; 3(4):263-4. PubMed ID: 12844447
    [No Abstract] [Full Text] [Related]

  • 32. Vaginal microbicides: how do you kick-start a global market?
    AIDS Anal Afr; 1996 Oct 01; 6(5):1. PubMed ID: 12347425
    [Abstract] [Full Text] [Related]

  • 33. [Microbicides and women].
    Iafolla M.
    Sidahora; 2002 Oct 01; (2):20-5. PubMed ID: 12772644
    [No Abstract] [Full Text] [Related]

  • 34. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease.
    Puntmann VO.
    Postgrad Med J; 2009 Oct 01; 85(1008):538-45. PubMed ID: 19789193
    [Abstract] [Full Text] [Related]

  • 35. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
    Mallipeddi R, Rohan LC.
    Expert Opin Drug Deliv; 2010 Jan 01; 7(1):37-48. PubMed ID: 20017659
    [Abstract] [Full Text] [Related]

  • 36. 'We need a microbicide now!'.
    Smart T.
    IAPAC Mon; 2006 Apr 01; 12(4):114. PubMed ID: 17233098
    [No Abstract] [Full Text] [Related]

  • 37. Microbicides now.
    Forrest S.
    Posit Living; 2001 Apr 01; 10(3):31-3, 38. PubMed ID: 11548374
    [No Abstract] [Full Text] [Related]

  • 38. Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides.
    Saidi H, Jenabian MA, Belec L.
    AIDS Res Hum Retroviruses; 2012 Nov 01; 28(11):1485-97. PubMed ID: 22867060
    [Abstract] [Full Text] [Related]

  • 39. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.
    Herold BC, Mesquita PM, Madan RP, Keller MJ.
    Am J Reprod Immunol; 2011 Mar 01; 65(3):325-33. PubMed ID: 21143689
    [Abstract] [Full Text] [Related]

  • 40. Discovery and development of biomarkers of neurological disease.
    Dunckley T, Coon KD, Stephan DA.
    Drug Discov Today; 2005 Mar 01; 10(5):326-34. PubMed ID: 15749281
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.